Immunomodulation therapy with lenalidomide in follicular, transformed and diffuse large B cell lymphoma: Current data on safety and efficacy

Journal of Hematology and Oncology

Volumn 6, Issue 1, 2013, Pages

  Desai, Madhav ^a   Newberry, Kate J ^a   Romaguera, Jorge ^a   Zhang, Liang ^a   Ou, Zhishuo ^a   Wang, Michael ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

B cell; Immunomodulatory; Lenalidomide; Lymphoma

Indexed keywords

LENALIDOMIDE; RITUXIMAB; VASCULOTROPIN;

ANTIANGIOGENIC ACTIVITY; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIGEN RECOGNITION; ANTINEOPLASTIC ACTIVITY; BURKITT LYMPHOMA; CANCER CHEMOTHERAPY; CANCER INHIBITION; DISEASE COURSE; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG SAFETY; EVENT FREE SURVIVAL; FATIGUE; FOLLICULAR LYMPHOMA; HUMAN; HYPONATREMIA; IMMUNOLOGICAL SYNAPSE; IMMUNOMODULATION; LARGE CELL LYMPHOMA; LYMPHOCYTOPENIA; MAINTENANCE THERAPY; MANTLE CELL LYMPHOMA; MULTICENTER STUDY (TOPIC); NEUTROPENIA; NONHODGKIN LYMPHOMA; OVERALL SURVIVAL; PERIPHERAL BLOOD MONONUCLEAR CELL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SURVIVAL RATE; TERATOGENICITY; THROMBOCYTOPENIA; THROMBOSIS; TUMOR MICROENVIRONMENT;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; HUMANS; IMMUNOMODULATION; LYMPHOMA, LARGE B-CELL, DIFFUSE; THALIDOMIDE; TUMOR MICROENVIRONMENT;

EID: 84880872904     PISSN: None     EISSN: 17568722     Source Type: Journal    
DOI: 10.1186/1756-8722-6-55     Document Type: Review

References (56)

1. Antitumor activity of thalidomide in refractory multiple myeloma. Singhal S, Mehta J, Desikan R, Ayers D, Roberson P, Eddlemon P, Munshi N, Anaissie E, Wilson C, Dhodapkar M, et al. N Engl J Med 1999 341 21 1565 1571 10.1056/NEJM199911183412102 10564685
2. Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. Rajkumar SV, Blood E, Vesole D, Fonseca R, Greipp PR, J Clin Oncol 2006 24 3 431 436 10.1200/JCO.2005.03.0221 16365178 (Pubitemid 46630462)
3. Development of neuropathy in patients with myeloma treated with thalidomide: patterns of occurrence and the role of electrophysiologic monitoring. Mileshkin L, Stark R, Day B, Seymour JF, Zeldis JB, Prince HM, J Clin Oncol 2006 24 27 4507 4514 10.1200/JCO.2006.05.6689 16940275 (Pubitemid 46630990)
4. Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: a phase III, open-label, randomized trial. Palumbo A, Cavo M, Bringhen S, Zamagni E, Romano A, Patriarca F, Rossi D, Gentilini F, Crippa C, Galli M, et al. J Clin Oncol 2011 29 8 986 993 10.1200/JCO.2010.31.6844 21282540
5. Thalidomide analogues as anticancer drugs. Aragon-Ching JB, Li H, Gardner ER, Figg WD, Recent Pat Anticancer Drug Discov 2007 2 2 167 174 17975653 (Pubitemid 46952433)
6. The evolution of thalidomide and its IMiD derivatives as anticancer agents. Bartlett JB, Dredge K, Dalgleish AG, Nat Rev Cancer 2004 4 4 314 322 10.1038/nrc1323 15057291 (Pubitemid 38525287)
7. Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma. Wiernik PH, Lossos IS, Tuscano JM, Justice G, Vose JM, Cole CE, Lam W, McBride K, Wride K, Pietronigro D, et al. J Clin Oncol 2008 26 30 4952 4957 10.1200/JCO.2007.15.3429 18606983
8. An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma. Witzig TE, Vose JM, Zinzani PL, Reeder CB, Buckstein R, Polikoff JA, Bouabdallah R, Haioun C, Tilly H, Guo P, et al. Ann Oncol 2011 22 7 1622 1627 10.1093/annonc/mdq626 21228334
9. Lenalidomide oral monotherapy produces durable responses in relapsed or refractory indolent non-Hodgkin's Lymphoma. Witzig TE, Wiernik PH, Moore T, Reeder C, Cole C, Justice G, Kaplan H, Voralia M, Pietronigro D, Takeshita K, et al. J Clin Oncol 2009 27 32 5404 5409 10.1200/JCO.2008.21.1169 19805688
10. Lenalidomide for the treatment of B-cell malignancies. Chanan-Khan AA, Cheson BD, J Clin Oncol 2008 26 9 1544 1552 10.1200/JCO.2007.14.5367 18285605
11. Lenalidomide inhibits proliferation of Namalwa CSN.70 cells and interferes with Gab1 phosphorylation and adaptor protein complex assembly. Gandhi AK, Kang J, Naziruddin S, Parton A, Schafer PH, Stirling DI, Leuk Res 2006 30 7 849 858 10.1016/j.leukres.2006.01.010 16494942 (Pubitemid 43816707)
12. Immunomodulatory drugs Revlimid (lenalidomide) and CC-4047 induce apoptosis of both hematological and solid tumor cells through NK cell activation. Zhu D, Corral LG, Fleming YW, Stein B, Cancer Immunol Immunother 2008 57 12 1849 1859 10.1007/s00262-008-0512-7 18392823
13. lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells. Wu L, Adams M, Carter T, Chen R, Muller G, Stirling D, Schafer P, Bartlett JB, Clin Cancer Res 2008 14 14 4650 4657 10.1158/1078-0432.CCR-07-4405 18628480
14. he use of the immunomodulatory drug, lenalidomide (Revlimid(R)) as a novel strategy to overcome acquired antibody resistance in rituximab-resistant non-Hodgkin's lymphoma (NHL) cell lines. Reddy NM, Hernandez-Ilizaliturri FJ, Czuczman MS, AACR Meeting Abstracts 2006 2006 1 154-a
15. Thalidomide and lenalidomide: mechanism-based potential drug combinations. Vallet S, Palumbo A, Raje N, Boccadoro M, Anderson KC, Leuk Lymphoma 2008 49 7 1238 1245 10.1080/10428190802005191 18452080 (Pubitemid 352015786)
16. Orally administered lenalidomide (CC-5013) is anti-angiogenic in vivo and inhibits endothelial cell migration and Akt phosphorylation in vitro. Dredge K, Horsfall R, Robinson SP, Zhang LH, Lu L, Tang Y, Shirley MA, Muller G, Schafer P, Stirling D, et al. Microvasc Res 2005 69 1-2 56 63 15797261 (Pubitemid 40410468)
17. Follicular lymphoma cells induce T-cell immunologic synapse dysfunction that can be repaired with lenalidomide: implications for the tumor microenvironment and immunotherapy. Ramsay AG, Clear AJ, Kelly G, Fatah R, Matthews J, Macdougall F, Lister TA, Lee AM, Calaminici M, Gribben JG, Blood 2009 114 21 4713 4720 10.1182/blood-2009-04-217687 19786615
18. Identification of a primary target of thalidomide teratogenicity. Ito T, Ando H, Suzuki T, Ogura T, Hotta K, Imamura Y, Yamaguchi Y, Handa H, Science 2010 327 5971 1345 1350 10.1126/science.1177319 20223979
19. Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide. Zhu YX, Braggio E, Shi CX, Bruins LA, Schmidt JE, Van Wier S, Chang XB, Bjorklund CC, Fonseca R, Bergsagel PL, et al. Blood 2011 118 18 4771 4779 10.1182/blood-2011-05-356063 21860026
20. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia. Plosker GL, Figgitt DP, Drugs 2003 63 8 803 843 10.2165/00003495-200363080-00005 12662126 (Pubitemid 36432084)
21. Synergistic antitumor effects of lenalidomide and rituximab on mantle cell lymphoma in vitro and in vivo. Zhang L, Qian Z, Cai Z, Sun L, Wang H, Bartlett JB, Yi Q, Wang M, Am J Hematol 2009 84 9 553 559 10.1002/ajh.21468 19565649
22. Immunomodulatory drug CC-5013 or CC-4047 and rituximab enhance antitumor activity in a severe combined immunodeficient mouse lymphoma model. Hernandez-Ilizaliturri FJ, Reddy N, Holkova B, Ottman E, Czuczman MS, Clin Cancer Res 2005 11 16 5984 5992 10.1158/1078-0432.CCR-05-0577 16115943 (Pubitemid 41170330)
23. Immunomodulatory drugs stimulate natural killer-cell function, alter cytokine production by dendritic cells, and inhibit angiogenesis enhancing the anti-tumour activity of rituximab in vivo. Reddy N, Hernandez-Ilizaliturri FJ, Deeb G, Roth M, Vaughn M, Knight J, Wallace P, Czuczman MS, Br J Haematol 2008 140 1 36 45 17995965 (Pubitemid 350233246)
24. Activity of thalidomide and lenalidomide in mantle cell lymphoma. Richardson SJ, Eve HE, Copplestone JA, Dyer MJ, Rule SAJ, Acta Haematol 2010 123 1 21 29 10.1159/000257990 19907157
25. Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph). Morton LM, Turner JJ, Cerhan JR, Linet MS, Treseler PA, Clarke CA, Jack A, Cozen W, Maynadie M, Spinelli JJ, et al. Blood 2007 110 2 695 708 10.1182/blood-2006-11-051672 17389762 (Pubitemid 47105409)
26. Howlader N, Noone AM, Krapcho M, Neyman N, Aminou R, Altekruse SF, Kosary CL, Ruhl J, Tatalovich Z, Cho H, et al. SEER Cancer Statistics Review, 1975-2009 (Vintage 2009 Populations) Bethesda: National Cancer Institute MD, http://seer.cancer.gov/csr/1975-2009-pops09/, based on November 2011 SEER data submission, posted to the SEER web site, April 2012 18718969
27. Follicular lymphoma. Harris N, Swerdlow S, Jaffe E, Ott G, Nathwani B, de Jong D, Yoshino T, Spagnolo D, WHO classification of tumours of haematopoietic and lymphoid tissues 2008 220 226
28. Natural history of follicular grade 3 non-Hodgkin's lymphoma. Bierman PJ, Curr Opin Oncol 2007 19 5 433 437 10.1097/CCO.0b013e3282c9ad78 17762566 (Pubitemid 47356597)
29. Lenalidomide and Rituximab for untreated indolent Lymphoma: final results of a phase II study. Fowler NH, Neelapu SS, Hagemeister FB, McLaughlin P, Kwak LW, Romaguera JE, Fanale MA, Fayad LE, Orlowski RZ, Wang M, et al. ASH Annual Meeting Abstracts 2012 120 21 901
30. High response rates with lenalidomide plus rituximab for untreated indolent B-cell non-Hodgkin lymphoma, including those meeting GELF criteria. Samaniego F, Hagemeister F, Mclaughlin P, Kwak LW, Romaguera J, Fanale MA, Neelapu SS, Fayad L, Orlowski RZ, Wang M, et al. J Clin Oncol suppl; abstr 8030
31. Activation of T and NK Cells Following Lenalidomide Therapy in Patients with Follicular Lymphoma. Rawal S, Fowler N, Zhang M, Wang Z, Muzzafar T, Harun N, Baladandayuthapani V, Sharma R, Delgado D, Wallace M, et al. ASH Annual Meeting Abstracts 2012 2012 120 2 2766
32. LENALIDOMIDE PLUS RITUXIMAB LEADS TO A HIGH RATE OF DURABLE RESPONSES IN PATIENTS WITH RELAPSED/REFRACTORY INDOLENT NON-HODGKIN'S LYMPHOMA. Dutia M, Deroock I, Reed-Pease C, Tuscano J, Ann Oncol 2011 22 186 186
33. Alliance for clinical trials in oncology: CALGB 50401: a randomized trial of lenalidomide alone versus lenalidomide plus rituximab in patients with recurrent follicular lymphoma. Leonard J, Jung S-H, Johnson JL, Bartlett N, Blum KA, Cheson BD, SCO Meeting Abstracts 2012 30 15
34. Oral Lenalidomide with rituximab in relapsed or refractory diffuse large cell, follicular, and transformed lymphoma: a phase II clinical trial. Wang M, Fowler N, Wagner-Bartak N, Feng L, Romaguera J, Neelapu SS, Hagemeister F, Fanale M, Oki Y, Pro B, et al. Leukemia 2013 [Epub ahead of print] 10.1038/leu.2013.95
35. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. Rosenwald A, Wright G, Chan WC, Connors JM, Campo E, Fisher RI, Gascoyne RD, Muller-Hermelink HK, Smeland EB, Giltnane JM, et al. N Engl J Med 2002 346 25 1937 1947 10.1056/NEJMoa012914 12075054 (Pubitemid 34651353)
36. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A, Boldrick JC, Sabet H, Tran T, Yu X, et al. Nature 2000 403 6769 503 511 10.1038/35000501 10676951 (Pubitemid 30082188)
37. Relapsed/refractory diffuse large B-cell lymphoma. Friedberg JW, Hematology Am Soc Hematol Educ Program 2011 2011 498 505 10.1182/asheducation- 2011.1.498 22160081
38. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. Gisselbrecht C, Glass B, Mounier N, Singh Gill D, Linch DC, Trneny M, Bosly A, Ketterer N, Shpilberg O, Hagberg H, et al. J Clin Oncol 2010 28 27 4184 4190 10.1200/JCO.2010.28.1618 20660832
39. Higher response to lenalidomide in relapsed/refractory diffuse large B-cell lymphoma in nongerminal center B-cell-like than in germinal center B-cell-like phenotype. Hernandez-Ilizaliturri FJ, Deeb G, Zinzani PL, Pileri SA, Malik F, Macon WR, Goy A, Witzig TE, Czuczman MS, Cancer 2011 117 22 5058 5066 10.1002/cncr.26135 21495023
40. Lenalidomide Efficacy in Activated B-Cell-Like Subtype Diffuse Large B-Cell Lymphoma Is Dependent Upon IRF4 and Cereblon Expression. Zhang L-H, Kosek J, Wang M, Heise C, Schafer PH, Chopra R, ASH Annual Meeting Abstracts 2012 120 21 3287
41. Combination of lenalidomide and rituximab in elderly patients with relapsed or refractory diffuse large B-cell lymphoma: a phase 2 trial. Zinzani PL, Pellegrini C, Gandolfi L, Stefoni V, Quirini F, Derenzini E, Broccoli A, Argnani L, Pileri S, Baccarani M, Clin Lymphoma Myeloma Leuk 2011 11 6 462 466 10.1016/j.clml.2011.02.001 21859554
42. A phase II randomized study of lenalidomide or lenalidomide and rituximab as maintenance therapy following R-CHOP chemotherapy for patients with high risk diffuse large B-cell lymphoma. Reddy NM, Simons RM, Caldwell ME, Chen H, Jagasia M, Morgan DS, Park SI, Greer JP, Richards KL, ASH Annual Meeting Abstracts 2012 120 21 3668-
43. Lenalidomide can be safely combined with R-CHOP (R2CHOP) in the initial chemotherapy for aggressive B-cell lymphomas: phase I study. Nowakowski GS, LaPlant B, Habermann TM, Rivera CE, Macon WR, Inwards DJ, Micallef IN, Johnston PB, Porrata LF, Ansell SM, et al. Leukemia 2011 25 12 1877 1881 10.1038/leu.2011.165 21720383
44. Combination of Lenalidomide with R-CHOP (R2CHOP) is well-tolerated and effective as initial therapy for aggressive B-Cell lymphomas-a phase II study. Nowakowski GS, LaPlant BR, Reeder C, Foran JM, Porrata LF, Macon WR, Johnston PB, Rivera CE, Habermann TM, Inwards DJ, et al. ASH Annual Meeting Abstracts 2012 120 21 689
45. The incidence, natural history, biology, and treatment of transformed lymphomas. Bernstein SH, Burack WR, Hematology Am Soc Hematol Educ Program 2009 532 541
46. The natural history of initially untreated low-grade non-Hodgkin's lymphomas. Horning SJ, Rosenberg SA, N Engl J Med 1984 311 23 1471 1475 10.1056/NEJM198412063112303 6548796 (Pubitemid 15211022)
47. MYC rearrangements in histologically progressed follicular lymphomas. Yano T, Jaffe ES, Longo DL, Raffeld M, Blood 1992 80 3 758 767 1638027
48. Population-based analysis of incidence and outcome of transformed non-Hodgkin's lymphoma. Al-Tourah AJ, Gill KK, Chhanabhai M, Hoskins PJ, Klasa RJ, Savage KJ, Sehn LH, Shenkier TN, Gascoyne RD, Connors JM, J Clin Oncol 2008 26 32 5165 5169 10.1200/JCO.2008.16.0283 18838711
49. The differential effect of lenalidomide monotherapy in patients with relapsed or refractory transformed non-Hodgkin lymphoma of distinct histological origin. Czuczman MS, Vose JM, Witzig TE, Zinzani PL, Buckstein R, Polikoff J, Li J, Pietronigro D, Ervin-Haynes A, Reeder CB, Br J Haematol 2011 154 4 477 481 10.1111/j.1365-2141.2011.08781.x 21707581
50. Lenalidomide and CC-4047 inhibit the proliferation of malignant B cells while expanding normal CD34+ progenitor cells. Verhelle D, Corral LG, Wong K, Mueller JH, Moutouh-de Parseval L, Jensen-Pergakes K, Schafer PH, Chen R, Glezer E, Ferguson GD, et al. Cancer Res 2007 67 2 746 755 10.1158/0008-5472.CAN-06- 2317 17234786 (Pubitemid 46192215)
51. Lenalidomide Enhances Anti-Tumor Effect of {gamma}{delta} T Cells against Mantle Cell Lymphoma. Gaidarova S, Corral LG, Gleizer E, Young D, Brady H, Bennett B, Lopez-Girona A, ASH Annual Meeting Abstracts 2008 112 11 2616
52. Direct Inhibitory Effects of Lenalidomide on the Proliferation and VEGF Production of Non-Hodgkin Lymphoma Cells Are Associated with Increased SPARC Expression. Zhang L-H, Schafer PH, Muller G, Stirling D, Bartlett B, ASH Annual Meeting Abstracts 2008 112 11 2612
53. Pomalidomide and lenalidomide induce p21 WAF-1 expression in both lymphoma and multiple myeloma through a LSD1-mediated epigenetic mechanism. Escoubet-Lozach L, Lin IL, Jensen-Pergakes K, Brady HA, Gandhi AK, Schafer PH, Muller GW, Worland PJ, Chan KW, Verhelle D, Cancer Res 2009 69 18 7347 7356 10.1158/0008-5472.CAN-08-4898 19738071
54. reatment of MCL Cells with Combined Rituximab and Lenalidomide Enhances NK-Mediated Synapse Formation and Cell Killing. Gaidarova S, Corral LG, Glezer E, Schafer PH, Lopez-Girona A, ASH Annual Meeting Abstracts 2009 114 22 1687
55. Anti-Proliferative and Apoptotic Activity of Lenalidomide in Combination with Rituximab in Follicular Lymphoma: an in Vitro and Ex Vivo Analysis in Follicular Lymphoma Cells. Gandhi AK, Kang J, Capone L, Shafarenko M, Schafer PH, ASH Annual Meeting Abstracts 2009 114 22 3723
56. Lenalidomide Induces Capping of CD20 and Cytoskeleton Proteins to Enhance Rituximab Immune Recognition of Malignant B-Cells. Gaidarova S, Mendy D, Heise C, Aukerman SL, Daniel T, Chopra R, Lopez-Girona A, ASH Annual Meeting Abstracts 2010 116 21 2845